GlobeNewswire

Sky9 Capital Closes New Fund on $200 Million Hard Cap

Dela

HONG KONG, April 24, 2018 (GLOBE NEWSWIRE) -- Sky9 Capital announced today that it has completed the final closing of Sky9 Capital Fund III, L.P. with total capital commitments of $200 million.  With support from a strong group of world-class institutional investors, family foundations and entrepreneurs, the fund invests mainly in China-based businesses with a focus on early-stage companies in the internet, enterprise, and deep technology sectors.  Ron Cao, Founder & Managing Director, has over 18 years of extensive experience in venture capital and a track record of investing and growing successful China-based companies. 

The Sky9 team includes an experienced group of technologists, entrepreneurs and investors who have participated previously in the early-stage investments of some of the biggest technology companies in China including: DaVdian, eBroker, FaceU/Toutiao, FangDD, Innolight, Meituan/Dianping, ManBang Group, PPDai, PinDuoDuo, QingCloud, Rong360, Tujia, ZhaoYouWang and others.  With presence in Beijing, Shanghai, Shenzhen, and Silicon Valley, the firm has made a number of investments in the new fund including: ZhaoYouWang, the leading B2B e-commerce platform for the petroleum industry; eBroker, China's largest online marketplace for wealth management; Home, the leading social e-commerce platform for home furnishing; and Energy Monster, a power bank sharing platform.  Continuing its focus on early-stage and high-impact technology companies, Sky9 Capital invests between $1M to $10M in seed and Series A rounds, and $10M+ for expansion-stage companies.

"Sky9 has an exceptional team, and we have the experience and the commitment to continue to explore and invest in the biggest technology opportunities in China today," said Ron Cao. "The size and scale of the China internet and technology space continue to be unprecedented.  We are honored to have the chance to work with some extraordinary entrepreneurs in building exceptional companies together."

"Ron was a lead venture investor in the early-stage financing of our company," said Cliff Zhang, Co-founder & CEO of PPDai, a leading FinTech platform in China. "He has helped us tremendously over the years as we built out our business.  We look forward to our continued partnership with Sky9's new fund."  

"Sky9 Capital is eBroker's most important investor and partner," said Max He, Founder & CEO of eBroker, China's leading online wealth management platform. "In addition to providing advice and strategic planning, Sky9 focuses on building long-term value and is a true partner in growing together.  Congratulations to Ron and team for the successful fundraise."

For more information, please visit www.sky9capital.com.

About Sky9 Capital:

Sky9 Capital is a leading venture capital firm focused on investing in early-stage internet, enterprise and deep-tech start-ups in China. The firm invests with a systematic, analytical and conviction-based approach, focused on drawing deep market insights and discovering China's top talents. These principles guide our presence in Beijing, Shanghai, Shenzhen, and Silicon Valley as we support the innovators who will shape our future.  Through many years of cultivating deep relationships in the internet and technology sector and through its network of advisors, limited partners and strategic partners, the Sky9 team closely collaborates and shares resources with China's industry leaders like Baidu, Alibaba, Tencent, Toutiao, Meituan/Dianping, PinDuoDuo, Ctrip, PPDai, Rong360, Xiaomi and more.  For more information, please visit www.sky9capital.com.

Contact:

Cindy Chen
T: (86) 21 5238 3699
E: cindy@sky9capital.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/8118babc-12f8-4e57-8275-56eba9528a2d




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sky9 Capital via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum